London, UK – 17th March 2021: Future Planet Capital has invested in a $168m Series B financing announced today by Vaccitech Ltd. Future Planet joins other leading investors including M&G Investment Management, Tencent, Gilead Sciences, Monaco Constitutional Reserve Fund and fellow existing investor, Oxford Sciences Innovation. As part of the Series B financing, $43 million in convertible loan notes previously issued by Vaccitech will convert into Series B shares, resulting in total gross proceeds to Vaccitech of $168 million before expenses.
Douglas Hansen-Luke Founder & EXec Chair
Future Planet Capital
Douglas Hansen-Luke, Executive Chairman of Future Planet Capital, explained:
"Our decision to support Vaccitech last year, before the results of the COVID-19 Vaccine AstraZeneca trials were known, has been vindicated by the vaccine’s approval for emergency use by national and international regulators. The success of the COVID-19 Vaccine AstraZeneca has increased our confidence in Vaccitech’s immunotherapy platform and our continuing support is signalled by our investment today.”
Bill Enright, CEO
Vaccitech
Bill Enright, CEO of Vaccitech, said:
“We expect this financing to enable us to reach key value inflection points for our lead programs. We now look forward to advancing key programs towards generating proof-of-concept data in indications with significant need of effective new treatments.”
Ed Phillips, Deal Lead
Future Planet Capital
Ed Phillips, Head of Origination at Future Planet Capital, concluded:
“This is a concrete example of our vision in action – financing the best minds to address global challenges. We look forward to working with other entrepreneurs and businesses dedicated to solving global challenges in the future.”
Vaccitech is a clinical stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer; in 2020 it co-invented a COVID-19 vaccine candidate with the University of Oxford, AZD1222, which is known as the COVID-19 Vaccine AstraZeneca.
-ends-
For further information, please contact;
Future Planet Capital: Ed Philips, Head of Origination: e.phillips@futureplanetcapital.com
Sciad Communications: Richard Anderson: richard@sciad.com, Emma Pickup: emma@sciad.com
